|
Abstract To study the effect of immunoglobulin combined with low molecular weight heparin for treating women with recurrent spontaneous abortion (RSA), and to analyze the changes of their levels of serum monocyte chemotactic protein-1(MCP-1), CC chemokine ligand 2 (CCL2) and CC chemokine receptor 4 (CCR4). Methods: 92 women with RSA were selected as research objects from March 2018 to March 2019. According to random number table，these women were divided into observation group (n=47) and control group (n=45). The women in the control group were treated with folic acid, while the women in the observation group treated with immunoglobulin combined with low molecular weight heparin except to folic acid. The uterine hemodynamics, the levels of human chorionic gonadotropin (β-hCG), progesterone (P), estradiol (E2), MCP-1, CCL2, and CCR4, the pregnancy outcomes, and the rates of complications and adverse reactions of the women were compared between the two groups. Results: After treatment, the values of PI, RI and S/D of uterine hemodynamics of the women in the observation group were 1.90±0.13, 0.76±0.11, and 3.98±0.51, which were significant lower than those (2.21±0.27, 0.82±0.13, and 5.17±0.78) of the women in the control group. The levels of β-HCG, P, and E2 of the women in the observation group were 7620.17±321.46U/L, 78.39±13.96μg/L, and 630.16±95.92ng/L, which were significant higher than those (6031.60±267.39U/L, 60.71±11.68μg/L, 531.07±86.28ng/L) of the women in the control group. The levels of MCP-1, CCl2, and CCR4 of the women in the observation group were 115.27±26.59 ng/mL, 62.57±5.36 pg/mL, and 75.85±15.08 ng/L, which were significant lower than those (132.96±30.61 ng/mL, 71.49±6.28 pg/mL, and 91.57±18.09 ng/L) of the women in the control group. The live birth rate (83.0%) of the women in the observation group was significant higher than that (62.22%) of the women in the control group, but the total incidence of ADR (17.0%) of the women in the observation group was significant lower than that (42.2%) of the women in the control group (all P＜0.05). Conclusion: Immunoglobulin combined with low molecular weight heparin for treating women with RSA can effectively improve their clinical symptoms, regulate their levels of E and P, and reduce the levels of serum MCP-1, CCL2, and CCR4, and the values of uterine hemodynamics indexes, improve their immune function, and promote pregnancy outcomes.
|
